GBS  logo
GBS GBS
report update icon

Quarterly report 2026-Q4
added 08-19-2026

GBS Financial Statements 2026-2011 | GBS

Annual Financial Statements GBS

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 248 K 749 K 39.3 K 286 K - - - - - - - - - - -

Shares

1.47 M 527 K 1.59 M 83.7 K 733 K 10.4 M - - - - - - - - - -

Historical Prices

- 0.47 0.47 0.47 0.39 0.46 5.98 - - - - - - - - -

Net Income

-12.4 M -10.6 M -10.2 M -10.6 M -8.31 M -7.04 M -3.13 M -7.34 M -5.02 M - - - - - - -

Revenue

4.22 M 3.05 M 3.11 M 1.26 M 437 K 1.98 M - - - - - - - - - -

Cost of Revenue

2.17 M 1.81 M 1.69 M 930 K - - - - - - - - - - - -

Gross Profit

2.05 M 1.25 M 1.43 M 327 K - - - - - - - - - - - -

Operating Income

-12.6 M -10.7 M -10.3 M -12.6 M -8.34 M -5.57 M -2.86 M - - - - - - - - -

Interest Expense

139 K 74.3 K - - - - - - - - - - - - - -

EBITDA

-11.4 M -9.47 M -9.31 M -11.8 M -8.34 M -5.57 M -2.71 M -6.73 M -4.6 M - - - - - - -

Operating Expenses

15.3 M 12.7 M 12.1 M 13.7 M 8.77 M 7.55 M - - - - - - - - - -

General and Administrative Expenses

10.5 M 8.92 M 9.26 M 8.03 M 38.9 K 3.36 M 2.43 M 3.55 M 2.08 M - - - - - - -

All numbers in USD currency

Quarterly Income Statement GBS

2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 1.59 M 951 K 8.55 M 951 K 8.55 M 732 K 5.77 M 454 K 3.81 M 3.46 M 2.08 M 950 K 194 K 194 K 92.4 K 75.7 K - 744 K 744 K 744 K 9.67 M 722 K 11.8 M 8.62 M 8.63 M 8.62 M 8.51 M 8.51 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- -2.86 M -2.68 M -2.98 M -2.68 M -2.98 M - -2.54 M -2.25 M -2.69 M - -2.98 M -1.97 M -2.43 M - -6.34 M -421 K -1.21 M -1.63 M -1.34 M -3.46 M -1.44 M -4.89 M -3.13 M -1.98 M -1.07 M -1.98 M -113 K -1.84 M -765 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- 1.06 M 897 K 1.11 M 897 K 1.11 M - 902 K 607 K 872 K - 908 K 917 K 906 K - 457 K 357 K - 357 K 192 K 178 K 373 K 178 K 34.3 K 283 K 55.4 K 283 K -1.53 K -798 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- 525 K 437 K 594 K 437 K 594 K - 387 K 384 K 525 K - 645 K 565 K 564 K - 424 K 113 K - 113 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- 535 K 460 K 518 K 460 K 518 K - 341 K 223 K 347 K - 178 K 199 K 232 K - 33 K 244 K - 244 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- -2.95 M -2.64 M -3 M -2.64 M -3 M - -2.55 M -2.26 M -2.73 M - -2.95 M -1.99 M -2.53 M - -6.54 M -2.13 M - -3.35 M -1.34 M -3.47 M -1.44 M -4.91 M -3.14 M -917 K -663 K -917 K -28.8 K -1.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- 77.5 K -50.9 K - -50.9 K - - - 7.68 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- -2.66 M -2.05 M -2.74 M -2.35 M -2.74 M - -2.25 M -1.96 M -2.48 M - -2.63 M -1.7 M -2.28 M - -6.14 M -1.73 M - -3 M -1.34 M -3.47 M -1.44 M -4.91 M -3.14 M -917 K -663 K -917 K -28.8 K -1.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- 3.65 M 3.17 M 3.71 M 3.17 M 3.71 M - 3.07 M 2.62 M 3.2 M - 3.22 M 2.34 M 2.87 M - 6.69 M 2.64 M - 4.17 M 1.54 M 3.64 M 1.44 M 5.08 M 3.17 M 1.2 M 718 K 1.2 M 27.3 K 1.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- 2.46 M 2.34 M 2.66 M 2.34 M 2.66 M - 2.41 M 1.81 M 1.95 M - 2.43 M 1.71 M 2.46 M - 1.9 M 2.25 M - 3.7 M 1.12 M 1 M 1.33 M 2.34 M 1.01 M 671 K 521 K 671 K 53.8 K 972 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements GBS GBS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting GBS plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
GenMark Diagnostics, Inc. GenMark Diagnostics, Inc.
GNMK
- - $ 1.77 B usaUSA
Lianluo Smart Limited Lianluo Smart Limited
LLIT
- 24.59 % $ 44.8 M chinaChina
Obalon Therapeutics, Inc. Obalon Therapeutics, Inc.
OBLN
- -5.86 % $ 30.6 M usaUSA
Hancock Jaffe Laboratories, Inc. Hancock Jaffe Laboratories, Inc.
HJLI
- -1.98 % $ 98.3 M usaUSA
EDAP TMS S.A. EDAP TMS S.A.
EDAP
- - $ 162 M franceFrance
CHF Solutions, Inc. CHF Solutions, Inc.
CHFS
- 1.15 % $ 34.5 M usaUSA
Soliton, Inc. Soliton, Inc.
SOLY
- -1.42 % $ 435 M usaUSA
Itamar Medical Ltd. Itamar Medical Ltd.
ITMR
- 0.03 % $ 1.58 B israelIsrael
Misonix, Inc. Misonix, Inc.
MSON
- - $ 462 M usaUSA
Intersect ENT, Inc. Intersect ENT, Inc.
XENT
- - $ 955 M usaUSA
CryoLife, Inc. CryoLife, Inc.
CRY
- -4.14 % $ 702 M usaUSA
Avanos Medical Avanos Medical
AVNS
$ 24.99 - $ 1.16 B usaUSA
Aziyo Biologics Aziyo Biologics
AZYO
- 1.37 % $ 20.5 M usaUSA
BioSig Technologies BioSig Technologies
BSGM
- 37.08 % $ 85.7 M usaUSA
Dynatronics Corporation Dynatronics Corporation
DYNT
- 14.99 % $ 929 K usaUSA
Second Sight Medical Products Second Sight Medical Products
EYES
- -0.97 % $ 54.4 M usaUSA
FONAR Corporation FONAR Corporation
FONR
- - $ 140 M usaUSA
NanoVibronix NanoVibronix
NAOV
- - $ 1.08 M usaUSA
Ra Medical Systems Ra Medical Systems
RMED
- 10.0 % $ 610 K usaUSA
ReWalk Robotics Ltd. ReWalk Robotics Ltd.
RWLK
- 7.07 % $ 66.1 M israelIsrael
STRATA Skin Sciences STRATA Skin Sciences
SSKN
- - $ 6.6 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
$ 76.5 0.76 % $ 4.17 B britainBritain